Benchmark downgraded NeoGenomics (NEO) to Hold from Buy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $18 from $21 at BTIG
- NeoGenomics Announces CEO Transition and Leadership Change
- NeoGenomics backs FY24 revenue view $655M-$667M, consensus $662M
- NeoGenomics CEO Chris Smith to retire, Tony Zook to succeed
- Natera expands patent infringement lawsuit against NeoGenomics